臨床研究等提出・公開システム

A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore the Safety, Pharmacokinetics, and Proof of Biological Activity of DS-7011a in Patients with Systemic Lupus Erythematosus

Phase 1b/2 Study of DS-7011a in Patients with Systemic Lupus Erythematosus (SLE)

Inoguchi Akihiro

Daiichi Sankyo Co., Ltd.

1-2-58, Hiromachi, Shinagawa-ku, Tokyo

dsclinicaltrial@daiichisankyo.co.jp

Contact for Clinical Trial Information

Daiichi Sankyo Co., Ltd.

1-2-58, Hiromachi, Shinagawa-ku, Tokyo

+81-3-6225-1111

dsclinicaltrial@daiichisankyo.co.jp

Not Recruiting

May. 01, 2024

Interventional

randomized controlled trial

double blind

placebo control

parallel assignment

treatment purpose

- Male and female subjects must be of 18 years or more with definite SLE for at least 6 months prior to Screening, defined according to the 2019 European League Against Rheumatism (EULAR)/ American College of Rheumatology (ACR) classification criteria for SLE3, including documented history of positivity for antinuclear antibody (titer >=1:80).
- Body mass index (BMI) >=18 kg/m^2 and body weight >=45 kg.
- Presence of active CLE (acute, subacute, and chronic cutaneous lupus) with active skin involvement and a CLASI-A score of 4 or higher at the time of Screening and randomization, as recognized by 2 adjudicators, despite adequate use of conventional therapies (either topical corticosteroids or antimalarial agents used for at least 12 weeks prior to Screening) or because of the requirement to discontinue these therapies due to side effects or poor tolerability.
- Subjects must be willing to have skin tape harvests collected from the affected skin area (skin tape stripping done on the target lesion).
- Subjects must be vaccinated against COVID-19.

- Active LN on induction therapy, or induction therapy completed within 12 weeks prior to Screening.
- Active neuropsychiatric SLE.
- Primary diagnosis of autoimmune or rheumatic disease other than SLE or drug-induced lupus.
- History of chronic, recurrent or recent serious infection, including viral infections, as determined by the investigator, or requiring anti-infective treatment within 12 weeks prior to Screening.
- History of severe herpes infection or signs of herpes or varicella zoster viral infection within 12 weeks prior to Screening.
- Positive COVID-19 molecular (polymerase chain reaction [PCR]) test at Screening or symptoms suggestive of SARS-CoV-2 infection or close contact with an individual with SARS-CoV-2 infection within 2 weeks prior to randomization.

Both

Systemic Lupus Erythematosus (SLE)

20 mg/kg, Intravenous infusions every 4 weeks (Weeks 0, 4, and 8)

safety and tolerability

pharmacokinetics, efficacy and immunogenicity properties

+81-52-691-7151

Feb. 26, 2024

Yes

De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/ Supporting Information: -Study Protocol -Statistical Analysis Plan (SAP) -Informed Consent Form (ICF) Time Frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication. Access Criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent. URL: https://vivli.org/ourmember/daiichi-sankyo/

United States/Macedonia/China